UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
Summary UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers. URGN's JELMYTO shows impressive clinical results with a 58% complete response rate for low-grade upper tract urothelial cancer, demonstrating long-lasting effects. URGN's diverse pipeline, including UGN-301 for high-grade NMIBC, positions the company for significant market expansion in urological cancer treatments. Currently, UGN-102 is in rolling FDA submission and targets a $5 billion market for LG-IR-NMIBC, with potential approval by Q1 2025. Despite regulatory risks, URGN's diverse pipeline and sufficient resources position it well for sustained long-term growth in the urothelial cancer therapy sector. TanyaRow/iStock via Getty Images UroGen Pharma ( NASDAQ: URGN ) develops innovative therapies for urological cancers. The company focuses on non-surgical treatment options that improve patient outcomes.
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now [Yahoo! Finance]Yahoo! Finance
- UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041Business Wire
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- UroGen Pharma to Present at Upcoming Investor ConferencesBusiness Wire
- UroGen Pharma: There Is Some Potential Here [Seeking Alpha]Seeking Alpha
URGN
Earnings
- 8/13/24 - Miss
URGN
Sec Filings
- 9/24/24 - Form 8-K
- 9/13/24 - Form 8-K
- 9/12/24 - Form 4
- URGN's page on the SEC website